FDA-approved1,2Evidence: Limited human dataHormones

Histrelin1

Also called Supprelin LA1,2

Key takeaway

Histrelin is a lab-made, more potent analogue of gonadotropin-releasing hormone (GnRH), a nine-amino-acid peptide, and the active ingredient in Supprelin LA.1,2 Supprelin LA is approved for children with central precocious puberty, in which puberty starts unusually early.1 Its approval rests on two small single-arm studies in children; in the larger, of 36 children, the main pubertal hormone was suppressed in every child through 12 months.1

Histrelin at a glance

What it isA synthetic nonapeptide analogue of gonadotropin-releasing hormone that, given continuously, suppresses the pituitary signals that drive puberty, according to the label.1
FDA statusFDA-approved. Drugs@FDA lists Supprelin LA, NDA 022058, with an original approval date of May 3, 2007. The cited label has no boxed warning.1,2
Human evidenceTwo single-arm, open-label studies in 11 and 36 children with central precocious puberty, described in the label.1
Evidence strengthLimited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned

What is histrelin?

Histrelin is a synthetic peptide of nine amino acids, an analogue of the natural gonadotropin-releasing hormone with greater potency, according to the label.1

In the United States it is the active ingredient of Supprelin LA, approved under NDA 022058, according to Drugs@FDA.2

How does histrelin work?

The label states that histrelin first stimulates the release of the pituitary hormones LH and FSH, then, with continuous exposure, desensitizes the pituitary so that ovarian and testicular hormone production falls.1

Because of that initial stimulation, the label warns that estrogen or testosterone may rise briefly at the start and temporarily worsen signs of puberty.1

What do human studies show?

The label describes two single-arm, open-label studies. In the larger, of 36 children (33 girls and 3 boys), LH was suppressed in every child from month 1 through month 12.1

Estradiol was suppressed in all 33 girls through month 9 and in 97% at month 12, and testosterone stayed suppressed in the 3 boys, according to the label.1

What the evidence base contains

  • Small, short, or incompletely reported human study Two single-arm, open-label studies in 11 and 36 children aged about 4 to 12 with central precocious puberty, without a comparison group, described in the label.1

Evidence-strength label: Limited human data. How this label is assigned

Is histrelin FDA-approved?

Yes. Drugs@FDA lists Supprelin LA, application NDA 022058, with an original approval date of May 3, 2007.2

The Supprelin LA label cited here (DailyMed SPL version 38, published September 29, 2025) states that it is indicated for the treatment of children with central precocious puberty.1

The label has no boxed warning. Its warnings include a temporary rise in sex hormones at the start, mood and behaviour changes such as irritability and aggression, and seizures reported with GnRH agonists.1

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Histrelin is not among them.3,4

Timeline

  1. FDA approves Supprelin LA, NDA 022058, according to Drugs@FDA.2
  2. DailyMed publishes the Supprelin LA label version cited on this page.1

What is still unknown?

How it compares with other treatments for central precocious puberty: the studies described in the label had no comparison group.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Histrelin: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Histrelin are a bounded selection, not every registration or paper about Histrelin. For the years before Histrelin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Histrelin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Histrelin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Supprelin LA for central precocious puberty. Two small single-arm studies in children described in the label found that it suppressed pubertal hormones through 12 months. The studies had no comparison group.↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Histrelin?

FDA-approved as Supprelin LA for central precocious puberty. Two small single-arm studies in children described in the label found that it suppressed pubertal hormones through 12 months. The studies had no comparison group.↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
9
Drugs@FDA applications
3

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Histrelin?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

10Selected dated records
14Connected citations
9Populated source years1991–2026
3/4Record lanes present

Registered human studies

Trial composition

1 of 1 selected trial records include at least one phase value; 1 of 1 include a status value in the retained structured contract.

PhasesPhase 3 1
Status at observationCompleted 1

PubMed bibliography

Publication composition

5 of 5 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 5Review 3Research Support, Non-U.S. Gov't 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
3
FDA Federal Register documents
1
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
10

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 10 dated records

Research hub

Explore the Histrelin evidence record

Open all 10 records →
10Dated records
3Evidence types
10Cited public sources
9Source years

Change ledger

Recently changed for Histrelin

Open all 10 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00779103

PeptideScanner retained ClinicalTrials.gov record NCT00779103 at 2026-11-16T01:35:22.086Z. Its registry update date was 2021-01-08, and PeptideScanner's reviewed identity mapping was histrelin.

PeptideScanner change date
November 16, 2026
Cited source date
January 8, 2021
Evidence lane
Clinical trials

Official-source collections

Source records for Histrelin

Open the full research atlas →

Evidence types

Coverage by source year

Selected records span December 24, 1991 to January 28, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2
  • U.S. Department of Health and Human Services3
Dated updates connected to this profile · 10

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Histrelin for central precocious puberty-a single surgeon experience.↗

    PubMed lists PMID 25899147 in The Journal of surgical research as Journal Article, with publication-date metadata of 2015-03-30 (day precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Histrelin: in advanced prostate cancer.↗

    PubMed lists PMID 20329807 in Drugs as Journal Article, Review, with publication-date metadata of 2010-03-26 (day precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT00779103↗

    PeptideScanner retained ClinicalTrials.gov record NCT00779103 at 2026-11-16T01:35:22.086Z. Its registry update date was 2021-01-08, and PeptideScanner's reviewed identity mapping was histrelin.↗

  4. Literature metadata

    Characterization of the solution degradation products of histrelin, a gonadotropin releasing hormone (LH/RH) agonist.↗

    PubMed lists PMID 2051345 in Journal of pharmaceutical sciences as Journal Article, with publication-date metadata of 1991-03 (month precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Histrelin. A review of its pharmacological properties and therapeutic role in central precocious puberty.↗

    PubMed lists PMID 7684676 in Drugs as Journal Article, Review, with publication-date metadata of 1993-04 (month precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    A review of the use of histrelin acetate in the treatment of prostate cancer.↗

    PubMed lists PMID 19228148 in BJU international as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2009-03 (month precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Regulatory

    Drugs@FDA application NDA022058↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 022058 with status AP dated 2007-05-03, and names histrelin acetate among the application record's active ingredients.↗

  8. Regulatory

    Drugs@FDA application NDA021732↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 021732 with status AP dated 2004-10-12, and names histrelin acetate among the application record's active ingredients.↗

  9. Regulatory

    Federal Register notice 03-20949↗

    The Federal Register published notice 03-20949, attributed to FDA and its parent HHS department, on 2003-08-18. Its official title is “Eli Lilly and Co. et al.; Withdrawal of Approval of 80 New Drug Applications and 75 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Histrelin and Secretin.↗

  10. Regulatory

    Drugs@FDA application NDA019836↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 019836 with status AP dated 1991-12-24, and names histrelin acetate among the application record's active ingredients.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    SUPPRELIN LA (histrelin acetate) implant · SPL version 38 · published 2025-09-29 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: SUPPRELIN LA (histrelin acetate), NDA 022058 · original approval May 3, 2007 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  4. 4
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026